PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), VEGF-B inhibitors(Vascular endothelial growth factor B inhibitors)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseEye Diseases+ [1]

Active Indication

Diabetic macular oedemaWet age-related macular degenerationRetinal Neovascularization

Inactive Indication-

Originator Organization

4D Molecular Therapeutics, Inc.

Active Organization

Sierra Eye Associates

4D Molecular Therapeutics, Inc.

Retina Vitreous Consultants

+ [1]

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationPRIME (EU), Regenerative Medicine Advanced Therapy (US)

Gene Sequence

Sequence Code 4715606

Clinical Trials associated with 4D-150

NCT05930561 / RecruitingPhase 2

A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Start Date09 Aug 2023

Sponsor / Collaborator

4D Molecular Therapeutics, Inc.

NCT05197270 / RecruitingPhase 1/2

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Start Date09 Dec 2021

Sponsor / Collaborator

4D Molecular Therapeutics, Inc.

100 Clinical Results associated with 4D-150

100 Translational Medicine associated with 4D-150

100 Patents (Medical) associated with 4D-150

Literatures (Medical) associated with 4D-150

02 Dec 2024·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies

Article

Author: Calton, Melissa A. ; Quezada, Melissa ; Klein, Austin ; Vazin, Tandis ; Mason, Thomas ; Kirn, David ; Burns, Christian ; Holt, Jenny ; Francis, Peter ; Croze, Roxanne H. ; Schaffer, David ; Khanani, Arshad M. ; Hassanipour, Mohammad ; Szymanski, Paul ; Schmitt, Christopher ; Barglow, Katherine ; Beliakoff, Ghezal ; Delaria, Katherine ; Leong, Meredith ; Khoday, Devi ; Bolender, Gabe ; Kotterman, Melissa

Purpose:

Intravitreal delivery of therapeutic transgenes to the retina via engineered viral vectors can provide sustained local concentrations of therapeutic proteins and thus potentially reduce the treatment burden and improve long-term vision outcomes for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy.

Methods:

We performed directed evolution in nonhuman primates (NHP) to invent an adeno-associated viral (AAV) variant (R100) with the capacity to cross vitreoretinal barriers and transduce all regions and layers of the retina following intravitreal injection. We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. Transduction, transgene expression, and biological activity were characterized in human retinal cells in vitro and in NHPs.

Results:

R100 demonstrated superior retinal cell transduction in vitro and in vivo compared to AAV2, a commonly used wild-type AAV serotype in retinal gene therapies. Transduction of human retinal pigment epithelial cells in vitro by 4D-150 resulted in dose-dependent transgene expression and corresponding reductions in VEGF-A and VEGF-C. Intravitreal administration of 4D-150 to NHPs was well tolerated and led to robust retinal expression of both transgenes. In a primate model of laser-induced choroidal neovascularization, 4D-150 completely prevented clinically relevant angiogenic lesions at all tested doses.

Conclusions:

These findings support further development of 4D-150. Clinical trials are underway to establish the safety and efficacy of 4D-150 in individuals with wet AMD and DME.

Genes

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond

Review

Author: Ciulla, Thomas ; Rowe, Lucas

Gene therapy holds promise as a transformative approach in the treatment landscape of age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME), aiming to address the challenges of frequent intravitreal anti-vascular endothelial growth factor (VEGF) injections. This manuscript reviews ongoing gene therapy clinical trials for these disorders, including ABBV-RGX-314, ixoberogene soroparvovec (ixo-vec), and 4D-150. ABBV-RGX-314 utilizes an adeno-associated virus (AAV) vector to deliver a transgene encoding a ranibizumab-like anti-VEGF antibody fragment, demonstrating promising results in Phase 1/2a and ongoing Phase 2b/3 trials. Ixo-vec employs an AAV2.7m8 capsid for intravitreal delivery of a transgene expressing aflibercept, showing encouraging outcomes in Phase 1 and ongoing Phase 2 trials. 4D-150 utilizes an evolved vector to express both aflibercept and a VEGF-C inhibitory RNAi, exhibiting positive interim results in Phase 1/2 studies. Other therapies reviewed include EXG102-031, FT-003, KH631, OLX10212, JNJ-1887, 4D-175, and OCU410. These therapies offer potential advantages of reduced treatment frequency and enhanced safety profiles, representing a paradigm shift in management towards durable and efficacious cellular-based biofactories. These advancements in gene therapy hold promise for improving outcomes in AMD and addressing the complex challenges of DME and DR, providing new avenues for the treatment of diabetic eye diseases.

EYE

Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues

Review

Author: Shirian, Jonathan D ; Shirian, Jonathan D. ; Shukla, Priya ; Singh, Rishi P. ; Singh, Rishi P

Abstract:

Neovascular age-related macular degeneration (nAMD) can lead to significant vision impairment through the growth of abnormal neovascular membranes in the choroid. Despite advancements with current anti-vascular endothelial growth factor (VEGF) therapies, challenges such as frequent injections, inadequate response, and patient-related concerns persist. Emerging therapeutics aim to reduce vision-loss through a variety of mechanisms. Gene therapies, including RGX-314 and Ixo-vec, express an anti-VEGF protein, and 4D-150, expresses an anti-VEGF protein and a VEGF-C inhibitory miRNA. Anti-VEGF associated therapeutics include OPT-302, targeting VEGF-C and VEGF-D, BI 836880, which inhibits VEGF-A and Ang-2 activity, and Tarcocimab tedromer, inhibiting all VEGF-A isoforms. Agents with novel mechanisms of action include UBX1325, which inhibits an anti-apoptotic protein, Restoret (EYE103), a Wnt agonist, and the tyrosine kinase inhibitors, EYP-1901, OTX-TKI, CLS-AX, and KHK4951.

News (Medical) associated with 4D-150

16 Dec 2024

·www.globenewswire.com

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicinesProprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all primate retinal cell layers after intravitreal injection in vivoIntravitreal administration of the R100 vector-based 4D-150 genetic medicine in nonhuman primate wet AMD model was well tolerated, led to robust retinal expression of dual transgenes (aflibercept and anti-VEGF C) and complete suppression of severe CNV choroidal neovascularization lesions4D-150 wet AMD (PRISM) and DME (SPECTRA) Phase 1/2 clinical trials are currently underway; 4FRONT Phase 3 program in wet AMD on target to initiate in Q1 2025 EMERYVILLE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced the publication of landmark preclinical data demonstrating the potential of the Company’s proprietary Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector and the R100-based genetic medicine 4D-150. Pioneering efficacy and safety results in a difficult-to-treat nonhuman primate (NHP) model of wet age-related macular degeneration (wet AMD) demonstrated the potential of 4D-150 to substantially reduce the treatment burden and improve long-term vision outcomes for patients with wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR). The data were published in Investigative Ophthalmology & Visual Science (IOVS); December 2024 issue. IOVS is the journal of the Association for Research in Vision and Ophthalmology (ARVO), a leading basic and translational research association in ophthalmology. The publication entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies,” reports the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: 1) a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B and PlGF, and 2) a microRNA sequence that inhibits expression of VEGF-C. The data showed that R100 demonstrated significantly superior human retinal cell transduction compared to AAV2, and intravitreal administration of 4D-150 to nonhuman primates was well tolerated and led to robust panretinal expression of both transgenes, especially within the macula region; AAV2 was unable to transduce deep retinal cell layers in the same model. In a difficult-to-treat primate laser-induced choroidal neovascularization model of wet AMD, 4D-150 completely prevented grade IV angiogenic lesions at all tested doses. “We founded 4DMT with the belief that the Nobel Prize-winning technology of directed evolution could be applied to invent highly optimized and customized AAV vectors for any tissue in the body. This proprietary Therapeutic Vector Evolution approach has been validated through clinical results with three different proprietary vectors for transgene payload delivery to the retina (R100, intravitreal), lung airways (A101, aerosol) and heart (C102, intravenous). R100 was invented to be a potentially best-in-class intravitreal vector to address and overcome the limitations of conventional vectors for the retina, and we are now leveraging R100 in our 4D-150 product candidate to potentially bring to market the first large market genetic medicine to transform vision outcomes for millions of patients with wet AMD and diabetic eye diseases,” said David Kirn, M.D., senior author of the paper and Co-founder and Chief Executive Officer of 4DMT. “This innovative disease-modifying genetic medicine is designed to continuously suppress all four major molecular drivers of these diseases for years, directly at the site of the disease within the macula, following a single routine clinic-based intravitreal injection. Standard of care bolus anti-VEGF therapies, which generate billions in annual sales, cannot achieve this transformative mechanism of action. The robust results in our primate models reinforce our confidence in 4D-150's efficacy in patients.” The publication is available online at the IOVS website and on the Scientific Publications page of the 4DMT website. About 4D-150 4D-150 combines our customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi. This dual-transgene payload inhibits four members of the VEGF angiogenic family of factors that drive wet AMD and DME: VEGF A, B, C and PlGF. R100 was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform; we developed this platform utilizing principles of directed evolution, a Nobel Prize-winning technology. 4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina without significant inflammation. About Wet AMD Wet AMD is a highly prevalent disease with estimated incidence rate of 200,000 new patients per year in the United States. It is estimated that the total prevalence of wet AMD in certain major markets, including the United States and the European Union (major markets), and Japan, will be greater than 4 million individuals in the next five years. Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a consequence, CNV causes swelling and edema of the retina, bleeding and scarring, and causes visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and can potentially destroy central vision and may progress to blindness without treatment. About DME DME is a highly prevalent disease with significant unmet medical need. It is estimated that there are approximately one million individuals with DME in the United States according to published data. DME is characterized by swelling in the macula due to leakage from blood vessels, which can lead to blurred vision. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks. About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT’s product candidates, and its R100, A101 and C102 vectors, as well as the plans, announcements, and related timing for the clinical development of, regulatory interactions regarding, and potential commercialization of 4D-150. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward looking statements. Contacts: Media:Katherine SmithInizio Evoke CommsMedia@4DMT.com Investors:Julian PeiHead of Investor Relations and Corporate FinanceInvestor.Relations@4DMT.com

Phase 3

19 Sep 2024

·endpts.com

4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision loss

4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial. The company on Wednesday reported updated Phase 1/2 data for its lead candidate, 4D-150, finding that 70% of treated patients in a broad Phase 2b population did not need an annualized injection of Regeneron’s Eylea. In that 30-patient group, 4DMT reported an 89% reduction in annualized injections through 52 weeks and said that 80% of patients received zero or one injection. The findings were even more pronounced in a 15-person cohort of patients who were recently diagnosed with wet age-related macular degeneration. 4DMT reported similar data in a Phase 1/2 population with more severe patients, including an 83% reduction in annual injections. More than half of patients had zero or one injection through 52 weeks and 44% were injection-free. In an interview, CEO David Kirn said the results are substantial evidence that its intravitreal injection — meaning it’s injected directly into the eye — is just as effective as other anti-VEGF candidates that require subretinal shots. Intravitreal injections are easier to perform than subretinal, which require surgery. “We’re thrilled to say we now have that,” he said. Though regulators only ask for data through 52 weeks, Kirn expects the effects of the therapy to be durable for five or more years. Investors were evidently less thrilled, with the company’s shares down 22% after the market opened Thursday. The injection did not lead to any new side effects and fit the safety profile of other anti-VEGF options, according to the California biotech. Roughly 3% of patients experienced intraocular inflammation, and all but one patient completed their steroid prophylaxis taper on time. All eyes are now on the company’s pivotal trials set for 2025. The first, a US-based study, is set to begin in the first quarter of next year. Kirn said that “we’re all aligned with FDA already.” He added that the company is “almost there” with European regulators and is hashing out final study details. That study would launch three or four months after the US one, Kirn said. Equipped with $578 million at the end of June , Kirn said there are no plans for a follow-on offering, a staple action for today’s public biotechs following positive readouts. “But we’ll be opportunistic and smart about how we build the business,” he said, adding that the company’s current runway extends through the first Phase 3 readout. Kirn also believes the company will have enough money to continue to advance earlier-stage candidates while prioritizing late-stage development of 4D-150. It has two other clinical-stage ophthalmology candidates in the pipeline, plus one that’s received IND clearance. 4DMT also has one clinical-stage candidate apiece for its pulmonary and cardiology wings. “We’re very rapidly shifting from a diversified company to what we hope to be the leader in large-market ophthalmology for genetic medicine,” Kirn said.

Phase 2Phase 3Clinical ResultGene Therapy

19 Sep 2024

·www.biopharmadive.com

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

Dive Brief:People with a common form of macular degeneration needed far fewer injections to manage their eye condition following treatment with an experimental gene therapy developed by 4D Molecular Therapeutics, the company said Wednesday.Study investigators found 4D Moleculars therapy reduced patients treatment burden by between 83% and 98%, depending on the severity of their disease and when they were diagnosed. The therapy, which is delivered via an eye injection, appeared to have a safety profile roughly in-line with available medicines, like Eylea and Vabysmo.4D Molecular also shared its plans for a Phase 3 study program of its gene therapy, which will involve two randomized trials comparing the experimental treatment to Eylea. However, investors didnt receive news of the data well, sending shares in the biotechnology company down by as much as 25% Thursday.Dive Insight:4D Molecular is one of a handful of developers testing genetic treatments for conditions of the eye. Seven years ago, the field produced the first gene therapy approved in the U.S. for an inherited disease, Spark Therapeutics Luxturna.But progress has been rockier since then, despite periodic investments by large pharmaceutical companies in biotechs like Spark that have driven research forward. A big acquisition by Biogen never panned out, as did another by Novartis. Several biotechs that have remained independent have hit either research or business roadblocks.4D Moleculars research is led by a treatment dubbed 4D-150, which its developing for wet age-related macular degeneration and diabetic macular edema. The results it unveiled Wednesday are in the former condition and come from several cohorts of patients enrolled in a Phase 1/2 trial.In wet AMD, 4D Moleculars goal is to lessen the frequent eye injections used to slow vision loss from the common condition, in which abnormal blood vessels grow into the center of the retina and cause visual distortion. Without treatment, the condition can eventually progress to blindness.4D focused its analysis of the results on the percentage of patients who remained injection free after its treatment, or needed only one supplemental injection. Among the 24 people with severe disease enrolled into the Phase 1/2a portion of the trial, 44% were injection free through one year. Overall, investigators reported an annualized reduction in injections of 83%. Those figures were 70% and 89%, respectively, in a broader group of 30 patients, and 98% and 87% among 15 newly diagnosed patients.Only 2 of the 71 patients overall who received the companys target dose of 4D-150 experienced intraocular inflammation, on the high end but within range of rates observed in testing of Eylea, Vabysmo and a new, longer-lasting formulation of Eylea.Analysts who follow 4D Molecular viewed the results as positive, but acknowledged a debate over how efficacious the companys treatment might ultimately be.Bears will point to eroding injection-free rates, especially in severe patients, while bulls will point to stabilization of efficacy in the post-24 week period, Mani Foroohar, an analyst at Leerink Partners, wrote in a client note, using the metonyms by which Wall Street refers to skeptics and optimists.Kelly Shi, an analyst at Jefferies, wrote that 4D-150s benefits seem correlated with disease severity, which she said should bode well for Phase 3 trials the company has planned. We think the highest bar is on safety, for which 4D continues to differentiate.4D Molecular said it plans to test 4D-150 in two Phase 3 studies that compare it to a once-every-two-month dose of 2 milligram Eylea. It expects to begin enrolling the first in the first quarter of next year.Regenxbio is also developing a gene therapy for AMD with partner AbbVie. Phase 3 studies are already underway. Adverum Biotechnologies is advancing a prospect towards late-stage testing as well. '

AcquisitionPhase 3Gene TherapyClinical ResultDrug Approval

100 Deals associated with 4D-150

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic macular oedema	Phase 2	US	4D Molecular Therapeutics, Inc.	09 Aug 2023
Diabetic macular oedema	Phase 2	PR	4D Molecular Therapeutics, Inc.	09 Aug 2023
Wet age-related macular degeneration	Phase 2	US	4D Molecular Therapeutics, Inc.	09 Dec 2021
Wet age-related macular degeneration	Phase 2	PR	4D Molecular Therapeutics, Inc.	09 Dec 2021
Retinal Neovascularization	Preclinical	US	4D Molecular Therapeutics, Inc.	16 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2024	Not Applicable	Wet age-related macular degeneration	-	4D-150 3x10¹⁰ vg/eye	zqdqnwsnuc(arokoaroej) = vijrktwdxy ilopymqfbc (ehohuzchtj ) View more	-	19 Sep 2024
				4D-150 1x10¹⁰ vg/eye	zqdqnwsnuc(arokoaroej) = eqrmpvhqfj ilopymqfbc (ehohuzchtj ) View more
NCT05197270 (PipelineReview) Manual	Phase 2	Wet age-related macular degeneration	45	4D-150	gjukwbfojt(kvcpsmojuq) = None ngaymoidgj (kklhnjtjbk ) View more	Positive	17 Jul 2024
NCT05197270 (PRISM, Corporate Publications) Manual	Phase 2	Wet age-related macular degeneration	51	4D-150 3E10 vg/eye	swbfxrjvbu(gnrwxarweo) = wczyfzwtmj mstrdjgyjs (qkbezphkku ) View more	Positive	03 Feb 2024
				4D-150 1E10 vg/eye	swbfxrjvbu(gnrwxarweo) = txpushrovf mstrdjgyjs (qkbezphkku ) View more
PRISM (GlobeNewswire) Manual	Phase 1/2	Wet age-related macular degeneration	15	4D-150 (3E10)	turyqlotgd(osuqyogfje) = 4D-150 was well tolerated, with no reported Grade ≥1 inflammatory cells and no hypotony, dose-limiting toxicities, or treatment-related serious adverse events zgdfmdzxes (hbjosmfffv )	Positive	29 Jul 2023
				4D-150 (1E10)
NCT05197270 (Biospace) Manual	Phase 1/2	Wet age-related macular degeneration	5	4D-150	nuemqsdhln(vbzzpahgvv) = cyndjbakxo fxlijzbygg (swwlhofkzv )	Positive	14 Nov 2022
4D-150 (ASGCT2021)	Not Applicable	Diabetic macular oedema \| Wet age-related macular degeneration	-	4D-150 (Vehicle)	sgkdxpbwti(raisiixves) = there was no evidence of chronic intraocular inflammation (uveitis) antcyprbif (mjwdaeczpr ) View more	Positive	27 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis